- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 21, 2023
Product Development
Vir’s first shot at ‘day one solution’ for influenza A misses Phase II endpoints
Prophylactic mAb was positioned as a bulwark against a potential flu pandemic
BioCentury | Jan 31, 2023
Distillery Therapeutics
A broadly acting neuraminidase-targeted mAb for influenza
BioCentury | Sep 6, 2022
Distillery Therapeutics
A single-dose inactivated whole-virus vaccine for influenza A
BioCentury | Dec 11, 2021
Product Development
Without clear differentiation, Moderna flu readout dents shares
First Phase I data for seasonal flu vaccine draw comparison to existing product, raise concerns about adverse events
BioCentury | Nov 7, 2020
Translation in Brief
Neoleukin’s ACE2 decoy protects hamsters from SARS-CoV-2; plus a circular RNA linked to diabetes and more
BioCentury’s roundup of translational news
BioCentury | Oct 3, 2020
Translation in Brief
A SARS-CoV-2 genome degrader; neutralizing influenza B mAbs; Fulcrum’s sickle cell therapy increases fetal hemoglobin and more
BioCentury’s roundup of translational news
BioCentury | Feb 13, 2020
Emerging Company Profile
Pneumagen: out-competing viral sugar binding to prevent infection
Pneumagen targeting infections, cancer by co-opting and enhancing microbial carbohydrate binders
BioCentury | Dec 5, 2019
Company News
Deerfield propels Civetta with $53M series A
How Civetta is using its series A from Deerfield to take on β-propeller proteins as a target class
BioCentury | Oct 24, 2019
Preclinical News
Oct. 24 Preclinical Quick Takes: anti-neuraminidase human antibodies for broad flu protection; plus Ionis-Baylor, Merck and more
BioCentury | Jul 25, 2019
Product Development
The universe of universal flu vaccines
How companies are broadening the reach of flu vaccines beyond seasonal strains
Items per page:
1 - 10 of 519